Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Dopamine agonists are usually very effective in the treatment of prolactinomas.
Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this …

Giant prolactinomas are rare tumours, representing only 2–3% of all prolactin (PRL)-
secreting tumours and raising special diagnostic and therapeutic challenges. Based on …

Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …

Abstract Context Approximately 10% to 20% of prolactinomas are resistant to dopamine
agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

BACKGROUND: Long-term remission rates from endoscopic transsphenoidal surgery for
acromegaly and their relationship to prognostic indicators of disease aggressiveness are not …

Pituitary adenomas are benign tumours comprising approximately 16% of all primary cranial
neoplasms. Functioning pituitary adenomas (prolactinomas, somatotroph, corticotroph …

The behaviour of lactotroph tumours varies between benign tumours, those cured by
treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of …

A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior,
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …